The San Diego-based biopharmaceutical company, Poseida Therapeutics, leverages proprietary gene engineering technologies to create therapeutics for illnesses with high unmet medical needs. Their pipeline includes autologous and allogenic CAR-T product candidates, with a focus on hematological malignancies and solid tumors. Their leading product candidate, P-BCMA-101, targets B cell maturation antigen expressed on multiple myeloma cells. They have also developed P-PSMA-101, which targets prostate-specific membrane antigen expressed on prostate cancer cells. In addition, Poseida has allogenic product candidates, P-BCMA-ALL01 and P-MUC1C-101, which are derived from healthy donors and offer benefits of scale and administration efficiency. The company plans to begin Phase 1 clinical trials for these candidates in late 2019 or early 2020. Poseida Therapeutics has filed documents for an IPO of $115 million and has formed collaborations with Roche and Takeda.